MFC — Manulife Financial Corporation

Manulife is a Canadian insurer whose stock price reflects the stagnant earnings trajectory of its North American legacy business while largely ignoring an Asia franchise that grew annualized new premiums 36% and core segment earnings 27% in its most recently completed year, in markets where insurance penetration sits at 3% against the 10–11% seen in developed Asian economies. At approximately ten times forward earnings — a meaningful discount to its Canadian insurance peers despite having the fastest-growing Asian operation among them — the combination of Asia optionality, a buyback that has been shrinking the share count at 4–5% annually, and a dividend yielding 4% creates a total return profile that is genuinely compelling. Compelling at the current price.

---

The life insurance industry's most recent years have told two distinct stories depending on geography. In North America and Europe, 2024 was a strong year by conventional measures: elevated interest rates fattened annuity spreads, group benefit operations ran near-normal claims ratios, and balance sheets recovered from the pandemic era's mark-to-market distortions. The returns were real but cyclical — products that lock in peak interest rates are sensitive to the direction of those rates, and the populations those businesses serve are not meaningfully growing. The consensus that North American life insurance is a low-growth, capital-intensive business generating mid-single-digit returns has not been disturbed.

Asia is a different story. Global life insurance gross written premiums grew 11.9% in 2024, their fastest pace in years, and Asia led the expansion. Mainland China's insurance premiums grew 15.4%. Vietnam, Indonesia, and the Philippines grew faster still. The structural driver is simple: insurance penetration in mainland China stands at approximately 3.28% of GDP. In Indonesia, it is below 3%. In Vietnam, below 2%. Japan, South Korea, and Hong Kong — markets with decades of established insurer presence, trained agency forces, and product maturity — show penetration rates of 10 to 12%. This gap is not explained by income alone. It reflects the early stage of a generational demand expansion that follows as the middle class grows, wealth accumulates, and awareness of longevity and health risk deepens. The insurers that established genuine distribution networks in these markets before the opportunity was obvious are now beginning to harvest what they seeded.

The global life insurance industry generated approximately $7.55 trillion in gross written premiums in 2024. At that scale, the business rewards incumbents more persistently than almost any other segment of financial services. A life insurance policy, once written, produces renewal premiums for years or decades. The insurer that wrote those policies first receives a compounding persistence benefit — the natural friction of established policy documents, beneficiary designations, and claims relationships — that a competitor cannot replicate without decades of patience. In most Asian markets, three or four providers control the dominant share of in-force premium, and that ranking shifts only at the margins. Distribution compounds the barrier further. A proprietary agency force of 100,000 trained agents represents a decade or more of recruiting, licensing, training, and field management investment. A preferred bancassurance agreement with the dominant regional bank was won through competitive bidding against every serious insurer in the world — and once secured, the channel is closed to those competitors until the contract expires.

Manulife Financial was incorporated in Toronto in 1887. Today it operates across four segments: an Asia insurance franchise spanning ten markets including Hong Kong, mainland China, Japan, Vietnam, Indonesia, and Singapore; a group benefits and individual insurance business in Canada; the John Hancock life and financial services operation in the United States; and Manulife Investment Management, a global asset management platform administering approximately CAD $1.26 trillion in total assets under management and administration. Revenue flows from the spread between investment returns and policyholder obligations, from underwriting margins on protection and group benefits, and from asset management fees largely insulated from insurance underwriting cycles. These segments are meaningfully different in their growth profiles. John Hancock is a North American franchise competing in a mature market where the strategic imperative is shedding legacy liabilities — primarily variable annuities and long-term care insurance written in prior decades under now-unfavorable actuarial assumptions — rather than capturing new growth. The Canadian group benefits business is profitable, stable, and subscale as a growth driver. The asset management platform generates recurring fee income that benefits from the long-run expansion of global investable assets. And the Asia segment, which generated CAD $1.9 billion in core earnings in 2024, is growing at the pace of a business that has barely started.

The competitive position of Manulife's Asia franchise rests on two types of assets with meaningfully different durability characteristics. The first is genuinely sticky. Manulife holds a 28.1% market share in Hong Kong's Mandatory Provident Fund as of June 2024 — the largest of any single provider — a regulatory retirement savings structure that locks employers into a provider relationship until they absorb the administrative cost and employee disruption of switching. A 28% share of a mandated, recurring contribution product in a wealthy market does not erode easily. The second asset — the exclusive bancassurance agreement with DBS Bank — is durable until 2031 and must then be re-won. In 2016, Manulife paid CAD $1.2 billion upfront to secure a fifteen-year exclusive partnership covering Hong Kong, Singapore, mainland China, and Indonesia. DBS is the dominant retail bank in Singapore and holds material market position in the other three jurisdictions. For Manulife, the deal provides capital-efficient distribution through established banking relationships in four key markets simultaneously. AIA, Prudential plc, and others bid competitively for this agreement and lost. In 2031, they will bid again. DBS's own behavior — reportedly shelving potential insurance partnerships in adjacent markets based on valuation concerns — suggests DBS negotiates from strength and does not feel compelled to extend loyalty to an incumbent. Manulife has incumbency, demonstrated execution, and a relationship now fifteen years deep. It does not have certainty.

Beyond these two anchors, the company operates approximately 116,000 agents across its ten Asian markets, supported by the ManulifePRO digital productivity platform, expanded in 2024 to Indonesia, Japan, and Hong Kong. The company reported approximately US$600 million in benefits from generative AI deployment across underwriting, claims, and operations in 2024 — a cost and productivity investment that smaller regional competitors cannot match at comparable scale.

The honest comparison to AIA is instructive but not comfortable. AIA, the largest independent pan-Asian life insurer by embedded value, operates across 18 Asian markets and generated a value of new business margin of 54.5% in 2024. Manulife's comparable figure was approximately 40.7%. That 14-percentage-point gap has two components. First, AIA's agency force is more heavily weighted toward high-value protection products — whole life, critical illness, medical coverage — that generate structurally higher per-policy margins than savings-linked products, where competition on price is more intense. Second, and more structurally significant, AIA's mainland China operation is structured as a wholly-owned foreign enterprise, allowing it to retain 100% of China's earnings contribution. Manulife's mainland China business operates through a joint venture, which means profits are shared with local partners and strategic flexibility is constrained. Beijing has not offered a WFOE license to a second foreign insurer. This is a structural gap that Manulife cannot close without a regulatory change that is not on the horizon.

Company	2024 New Business Value	YoY Growth	NBV / VONB Margin	Core / Underlying ROE
Manulife (MFC)	C$3.1B group / C$1.6B Asia	+32% group / +35% Asia	~40.7%	16.4%
AIA Group	US$4.7B	+18%	54.5%	— (EV-based)
Prudential plc	US$3.1B	+11%	~45%	— (EV-based)
Sun Life (SLF)	not disclosed	+18% new business CSM	not reported	17.2%

Manulife grew new business value 32% in 2024 against AIA's 18%. Volume growing faster than a structurally superior competitor is not the same as closing the structural gap — per-unit value creation remains lower, and the margin differential compounds over time — but it does mean Manulife is capturing market share aggressively in underpenetrated markets where simpler, savings-oriented products may be the appropriate first product for first-time insurance buyers. The higher-margin protection products that AIA sells in Hong Kong and mainland China with established trust and brand recognition typically follow once a customer relationship is established. The margin gap is real; it does not make the growth thesis false.

The financial profile of the group reflects both the Asia momentum and the ongoing transition away from the North American legacy. Manulife reported core earnings of CAD $7.2 billion in 2024, growing 8% on a constant-currency basis. In 2025, core earnings reached a record CAD $7.5 billion, though the growth rate moderated to approximately 3% constant currency, reflecting the strength of the 2024 base and currency headwinds as the U.S. dollar strengthened against both the Canadian dollar and Asian currencies. Core return on equity stood at 16.4% in 2024, below management's 2027 target of 18% but on a consistent upward trajectory from the 11–12% range of the early post-pandemic years.

The distinction between GAAP and core earnings matters at Manulife and warrants explicit treatment. GAAP earnings include mark-to-market movements in the investment portfolio, changes in the carrying value of insurance liabilities tied to discount rates, and recognition effects under IFRS 17. Core earnings strip out the market-driven fluctuations to isolate the underlying economics of the insurance and asset management operations. This is standard practice for IFRS 17 reporters, and the reconciling items are disclosed transparently. The core earnings figure is the more useful measure of ongoing earning power; a persistent and widening gap between GAAP and core over time would warrant reassessment, but no such pattern is currently present.

The balance sheet has been systematically de-risked in a way that represents genuine strategic execution rather than accounting cosmetics. Between 2022 and 2025, Manulife transferred legacy interest-rate-sensitive liabilities to reinsurers through a sequence of transactions that released capital for redeployment to share repurchases in each case. The variable annuity reinsurance with Venerable, executed across two tranches in 2022, transferred over US$22 billion in John Hancock account value and released approximately CAD $2.5 billion of capital. A transaction with Global Atlantic, closed in early 2024, was described at announcement as the largest long-term care reinsurance deal in industry history: US$6 billion in LTC reserves plus related structured settlement and Japan whole-life blocks, releasing CAD $1.2 billion. A follow-on deal with RGA in late 2024 reinsured an additional US$1.9 billion of LTC and US$2.2 billion in structured settlements, releasing CAD $0.8 billion. Combined, the LTC book has been reduced by approximately 20% from prior peak levels. The directional trajectory — consistently toward further reduction rather than accretion — matters more than the remaining absolute exposure.

Roy Gori ran Manulife for eight years before announcing his retirement in May 2025, succeeded by Phil Witherington. The capital allocation record across those eight years is unambiguous in its shareholder orientation. Buybacks accelerated each year as reinsurance transactions freed capital: CAD $1.9 billion in 2022 (79 million shares), CAD $1.6 billion in 2023 (62 million shares), and CAD $3.2 billion in 2024 (88 million shares at an average of C$39.11 — more than 20% below today's price). Total capital returned to shareholders in 2024 alone reached CAD $6.1 billion. Shares outstanding fell from approximately 1,806 million at end-2023 to 1,729 million at end-2024. The 2025 normal course issuer bid was fully exhausted by January 22, 2026 at an average repurchase price of C$44.28. The common dividend increased 11% in 2022, 9.6% in 2023, and 10% in 2024. The "Next Phase" strategy, launched in 2021 with a stated target of having highest-potential businesses represent 75% of group core earnings by 2025, was delivered: the actual figure reached 76%. Witherington inherits a business generating record core earnings, carrying materially less legacy liability risk than when Gori took over, and executing above its own stated targets. His target compensation was set at approximately US$9.7 million — roughly half of Gori's realized pay — a reset that suggests the board is not pricing in a turnaround.

The Asia growth trajectory is best tracked through three variables that directly reflect the business-building process: annualized premium equivalent sales, which measure the volume of new insurance written; new business value, which adjusts for margin quality; and core segment earnings, which prove that prior cohorts of new business are translating into actual cash profit as expected. A rising NBV at stable or expanding margins means volume growth without quality sacrifice. A rising core earnings figure confirms that earlier new business is maturing on actuarial expectation.

Year	Asia APE Sales	Asia New Business Value	Asia Core Earnings	Group Core Earnings
2022	~C$2.9B (est.)	~C$0.9B (est.)	~C$1.2B (est.)	C$6.2B
2023	~C$3.2B*	~C$1.2B*	~C$1.5B*	~C$6.7B*
2024	C$4.4B	C$1.6B	C$1.9B	C$7.2B
2025	—	—	—	C$7.5B

* 2023 Asia segment figures derived from 2024 reported growth rates (+36% APE, +35% NBV, +27% core earnings). 2022 Asia figures estimated from trend and industry context. 2024 group and Asia figures per reported results; 2025 group per reported results.

The numbers show a business that accelerated into 2024 after a period of more modest recovery. Asia core earnings grew from an estimated C$1.2 billion in 2022 to C$1.9 billion in 2024 — a 58% increase over two years. Annualized premium equivalent sales grew roughly 52% over the same period, with the growth markedly concentrated in the 2023-to-2024 step: the 36% annual increase in 2024 compares to a far more modest 2022-to-2023 pace. The 2024 acceleration reflects the full reopening of Hong Kong's border with mainland China following pandemic-era restrictions, which unlocked pent-up demand from mainland Chinese visitors purchasing high-value whole life and critical illness policies in Hong Kong — a historically significant channel that had been essentially closed for three years. New business CSM in Asia grew 38% in 2024. These are not rounding-error improvements; they are step-change volumes that validate the distribution investments Manulife made during the years when the channel was closed.

The penetration argument requires an explicit number. In Manulife's four core underpenetrated growth markets — mainland China, Vietnam, Indonesia, and Malaysia — insurance penetration averages approximately 3% of GDP against the 10–11% seen in Japan and South Korea. Against a combined population of more than 1.7 billion people in those four markets, the entire industry's presence is, by any long-run measure, embryonic. If China's insurance penetration were to converge toward Malaysian levels — roughly 4–5%, itself still well below Japan — the absolute size of the Chinese premium pool would roughly double from current levels. Manulife does not need to dominate that incremental demand. It needs to maintain a credible, well-distributed presence in a market that is structurally growing toward multiples of today's size. The DBS bancassurance partnership in China and Indonesia and the 116,000-agent network across ten markets represent a starting position that cannot be replicated by a competitor on a five-year horizon.

At USD $34.90 (CAD $48.57) as of April 2026, Manulife trades at a market capitalization of approximately USD $58.5 billion (CAD $81.4 billion). Against trailing twelve-month core earnings, the stock carries a multiple of approximately 15.3x. Against forward earnings reflecting the market's expectation of continued growth, the multiple compresses to approximately 10.6x — the lowest of the three major publicly traded Canadian life insurers. At the current quarterly dividend of approximately C$0.44 per share, the yield is approximately 3.99% in Canadian dollar terms. Book value per share implies a price-to-book ratio of 1.53x.

Sun Life Financial — whose strategic profile most closely resembles Manulife's, with meaningful Asia and global wealth management exposure — trades at 1.90x book and 11.3x forward earnings. Great-West Lifeco, with minimal Asian exposure and a more stable but slower-growing earnings base, trades at 1.80x book and 12.0x forward earnings. Manulife is the cheapest of the three on both price-to-book and forward earnings, despite having the fastest-growing Asian franchise and the most aggressive capital return program. The discount to Sun Life on book value is particularly striking: if the market prices Sun Life at 1.90x book for an Asian operation that grew new business CSM 18% in 2024, and Manulife at 1.53x book for one that grew Asia NBV 35%, either the Sun Life multiple is generous or the market is applying a legacy liability discount to Manulife that is larger than the remaining actual liability warrants — or both.

The intelligent bear argues that the stock has already run 65% from early 2025 lows and the obvious re-rating has been consumed. At C$28, the market priced in essentially no Asia optionality. At C$49, it prices in some. The multiple on normalized pre-tax earnings — roughly 9x using trailing core earnings and an estimated effective tax rate of approximately 20% — remains comfortably inside the threshold at which growth is given for free rather than paid for in the entry price. At 9x normalized pre-tax earnings with a 4% dividend yield and a 4–5% annual buyback compression of the share count, the total return arithmetic runs to approximately 16–18% annually before any multiple expansion. The bear case requires a DBS non-renewal, a sustained reversal of Hong Kong mainland Chinese visitor demand, or a forced LTC reserve charge large enough to disrupt the buyback. None of these is imminent. The DBS risk is a 2031 event with genuine uncertainty but no near-term crisis; the mainland Chinese visitor channel has proved resilient through years of geopolitical noise; and the LTC book is trending downward through systematic reinsurance. The bear is paid to worry about these risks. At 9x pre-tax earnings, the investor is also being paid to hold through them.

What would need to change to alter this conclusion: a DBS non-renewal announced before 2030, a material and sustained decline in Hong Kong sales driven by mainland access disruption or regulatory pressure, or a reserve adequacy event requiring a capital charge large enough to terminate the buyback program. Any of these would reduce the thesis to a slower-compounding dividend story at a valuation that is reasonable but not exceptional. The probability of any one materializing within the next three years is real but not dominant.

At nine times normalized pre-tax earnings, with an Asia franchise growing at 25–35% in markets where the terminal penetration level is three to four times the current one, Manulife is priced for patience rather than excitement — and patience here is likely to be well rewarded.